Published in

Lippincott, Williams & Wilkins, Journal of Acquired Immune Deficiency Syndromes, 5(62), p. 505-508, 2013

DOI: 10.1097/qai.0b013e318285cd33

Links

Tools

Export citation

Search in Google Scholar

Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T cell activation

Journal article published in 2013 by Michael J. Vinikoor, Anna Cope, Cynthia L. Gay, Guido Ferrari, Kara S. McGee, Joann D. Kuruc, Jeffrey L. Lennox, David M. Margolis ORCID, Charles B. Hicks, Joseph J. Eron
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Initiation of ART during acute HIV-1 infection may prevent persistent immune activation. We analyzed longitudinal CD38+HLA-DR+ CD8+ T cell percentages in 31 acutely infected individuals who started early (median 43 days since infection) and successful ART, and maintained viral suppression through 96 weeks. Pre-therapy a median of 72.6% CD8+ T cells were CD38+HLA-DR+, and while this decreased to 15.6% by 96 weeks, it remained substantially higher than seronegative controls (median 8.9%, p=0.008). Shorter time to suppression predicted lower activation at 96 weeks. These results support the hypothesis that very early events in HIV-1 pathogenesis may result in prolonged immune dysfunction.